Veru Inc.
Long

VERU (breast cancer treatment) calendar spread idea

269
VERU is an oncology bio pharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer. It announced the presentation of pre-clinical data demonstrating the efficacy of oral VERU-111 in the treatment of human derived animal models of triple negative breast cancer. VERU reported on 12/9/20 Q4 earnings loss of $0.01 per share on revenue of $11.7 million. The consensus estimate was a loss of $0.05 per share on revenue of $10.6 million. That's a +80% eps surprise. Revenue grew 34.6% on a year-over-year basis.

This is a speculative risky play. My idea is a VERU calendar spread:
buy $10 call 1/15/21
sell $12.50 call 12/18

The worst thing that could happen this week would be a credit of $250 per spread on 12/18. Otherwise, your risk is $145 till 1/15/21. Or you can simply dca shares each day this week according to your indicators.

Do your own due diligence, your risk is 100% your responsibility. You win some or you learn some. Consider being charitable with some of your profit to help humankind. Small incremental steps work : If you double a penny / a day, for a month it = $5,368,709. Good luck and happy trading friends...

*3x lucky 7s of trading*

7pt Trading compass:
Price action, entry/exit
Volume average/direction
Trend, patterns, momentum
Newsworthy current events
Revenue
Earnings
Balance sheet

7 Common mistakes:
+5% portfolio trades, risk management
Beware of analysts motives
Emotions & Opinions
FOMO : bad timing
Lack of planning & discipline
Forgetting restraint
Obdurate repetitive errors, no adaptation

7 Important tools:
Trading View app!, Brokerage UI
Accurate indicators & settings
Wide screen monitor/s
Trading log (pencil & graph paper)
Big organized desk
Reading books, playing chess
Sorted watch-list

Checkout my indicators:
Fibonacci VIP - volume
Fibonacci MA7 - price
pi RSI - trend momentum
tradingview.com/u/growerik/

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.